CIDP

(redirected from Chronic inflammatory demyelinating polyneuropathy)
Also found in: Dictionary, Medical, Acronyms, Wikipedia.

CIDP

Crop Insurance and Disaster Payments. Any payments one receives from an insurance policy covering agricultural real estate. One lists CIDP on Form 4835 or Schedule F.
References in periodicals archive ?
The report reviews key players involved in the therapeutics development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and enlists all their major and minor projects
A review of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population.
Post influenza vaccine chronic inflammatory demyelinating polyneuropathy.
Dyck et al coined the phrase chronic inflammatory demyelinating polyneuropathy (5) several years after they reported the first case series of 53 patients with this disease complex.
Chronic inflammatory demyelinating polyneuropathy is a neurological disorder often characterized by progressive weakness and impaired sensory function in the legs and arms.
Food and Drug Administration (FDA) has granted approval for Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).
Research suggests that SF-1019 has analgesic properties with a perceived ability to substantially reduce the inflammation present in a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders.
Chronic Inflammatory Demyelinating Polyneuropathy Information Center Offers the Only Resource of Its Kind, Providing Comprehensive Information about CIDP
The inaugural Talent grants will fund a variety of studies ranging from basic cellular mechanisms by which IGIV mediates immune response, to a multicenter clinical registry to establish the efficacy of IGIV in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who do not meet normal diagnostic criteria.
The Company's broad platform technology also includes the development of products for multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy (CIDP) and amyotrophic lateral sclerosis (ALS).
The Company's broad platform technology also includes the development of products for multiple sclerosis, chronic inflammatory demyelinating polyneuropathy and amyotrophic lateral sclerosis.
Full browser ?